Sarah Ketterer, founder of Causeway Capital, is increasingly focusing on defensive stocks after the rally in cyclical sectors. The value investor explains why she sees potential in European pharmaceutical stocks such as Novartis and Roche in particular, why she is staying with ABB and what she expects from the new Chairman of the Board of Directors of Credit Suisse.
–
